Morus has raised US$5m in Series A funding to accelerate clinical trials and scale mass production of its proprietary silkworm-derived bioingredient, MorSilk Powder – a nutrient-dense powder with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results